Views & Analysis Considerations for Mobile Health Technology Developers: Part... In Part 1 of this series, general wellness devices and mobile me
Views & Analysis Considerations for Mobile Health Technology Developers: Part... In Part 1 of this series, general wellness devices and mobile medical applications (MMAs) will be considered. Part 2 of this series will be devoted to clinical decision support (C
Views & Analysis The real conspiracy in the pharma industry Paul Tunnah on how pharma industry workers can negatively affect patients without even realising it.
Partner Content Partner Content PLIVA explores impact of EU Guidelines on evaluation of modi... PLIVA explores EU Guidelines for modified release drugs
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
